Machiko Morita

Machiko Morita

Auto-generated profile, based on publicly available information

Machiko Morita

Department of Pediatrics, Saitama Medical Center, Saitama Medical University, Saitama, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Interdisciplinary Neurosurgery
Verified
Journal Article
Open access
MMMachiko Morita
Machiko Morita
Ayataka FujimotoAyataka Fujimoto
Ayataka Fujimoto
TOTohru Okanishi
Tohru Okanishi
MNMitsuyo Nishimura
Mitsuyo Nishimura
KSKeishiro Sato
Keishiro Sato
HEHideo Enoki
Hideo Enoki
Acute encephalitis with refractory, repetitive partial seizures (AERRPS) is a rare condition. The seizure control of this encephalopathy is poor. The purpose of this report is to evaluate the utility of vagus nerve stimulation (VNS) in a patient with AERRPS. A 14-year-old boy presented with fever and headache. He developed epileptic facial twitching and eyelid fluttering. Various types of antiepileptic drugs did not control his seizures. He underwent VNS at the age of 21. After 5 years of VNS therapy, his seizure frequency decreased from daily to monthly. For patients with AERRPS, VNS may be a treatment option

27 January 2020 in American Journal of Perinatology Reports
Verified
Journal Article
Open access
PDF file
AOAyumi Oshima
Ayumi Oshima
SMShun Matsumura
Shun Matsumura
AIAyaka Iwatani
Ayaka Iwatani
MMMachiko Morita
Machiko Morita
SFSumie Fujinuma
Sumie Fujinuma
FNFumihiko Namba
Fumihiko Namba
Background Although indomethacin and ibuprofen are the standard treatments for hemodynamically significant patent ductus arteriosus (hsPDA), they are associated with renal impairment and gastrointestinal complications. Paracetamol for hsPDA closure does not provoke a peripheral vasoconstrictive effect and seems to have effects similar to those of indomethacin and ibuprofen. We have previously reported the safety of low-dose (7.5 mg/kg) intravenous paracetamol for preterm infants with hsPDA, who were indomethacin-resistant or -contraindicated but did not affect the need for surgical PDA ligation. However, reports considering the use of higher-dose (15 mg/kg) paracetamol for hsPDA have not been published in Japan. Cases In 16 premature infants in whom indomethacin or ibuprofen was contraindicated or ineffective, 15 mg/kg of paracetamol was intravenously administered every 6 hours for 3 days after obtaining parental consent. hsPDA closure or narrowing was observed in 14 infants (88%), with the need for surgical closure totally avoided in nine cases (56%). High plasma paracetamol levels were observed in three cases. No paracetamol-related side effects or adverse events were reported. Conclusion The intravenous administration of higher dose paracetamol was safe and feasible in premature infants with hsPDA. Future clinical trials to explore the optimized dose and timing of administration are needed.